5nance5nance
5nance5nance
HomeScreens
LOGINGET FREE ACCOUNT

Natco Pharma Ltd.

•
natcopharma.co.inBSE: 524816NSE: NATCOPHARM
Market Cap₹ 14,599 Cr.
Current Price
High / Low₹ 1,227 / 789
Stock P/E16.4
Book Value₹ 482
Price to Book2.04
Dividend Yield0.61 %
ROCE16.6 %
ROE16.1 %
Face Value₹ 2

Add ratio to table

ABOUT

AI Sector View

AI GENERATED

Healthcare

Buy

This stance relies on proxies and positioning because no direct pharma-export or healthcare operating series exists in the dataset. The depreciated currency at 95.23 (Sep/26) can support export earnings, inflation at 4.45% (Jul/26) is manageable for a defensive sector, and consumer spending remains large at INR 44743 billion (Jun/26). Strong FPI inflow of INR 10620 crore over 3 months to 2026-08-31 from INR -11381 crore in the prior 3 months adds a real sector-specific tailwind, but confidence stays capped because the fundamental drivers are indirect proxies.

Confidence
50%
View full sector analysis →

PROS

  • Company has delivered good profit growth of 32.9% CAGR over last 5 years
  • Company is almost debt free
  • Company has a healthy return on capital (ROCE) of 26.2%
  • Company has a good return on equity (ROE) track record: 3 Years ROE 23.4%
  • Company has delivered good sales growth of 16.8% CAGR over last 5 years
  • Strong cash generation - operating cash flow backs reported profits (CFO/PAT 1.04x)

CONS

  • Recent results are weak - TTM profit is down 49.4% versus prior year
  • Total debt has risen sharply - up 158.7% year on year
  • Operating margins have contracted to 33.1% from 38.8%
  • Though reporting repeated profits, the company pays out little dividend (7.0%)

* The pros and cons are machine generated based on quantitative rules.

Peer comparison

HealthcareHealthcarePharmaceuticals & Drugs
Part ofNIFTY TOTAL MKTNIFTY SML250 Q50NIFTY SMLCAP 50NIFTY 500NIFTY SMLCAP 250
S.No.Name
1.SUNPHARMA1842.0036.54441957.500.872901.2326.5315299.8810.9819.1128.81
2.DIVISLAB9326.0084.64247576.000.32902.0065.503080.0027.8021.5140.75
3.TORNTPHARM4975.0086.76189233.010.76566.003.284921.0057.3219.2733.81
4.ZYDUSLIFE1119.5024.74111670.550.09990.20-34.908017.0023.9721.3924.54
5.CIPLA1365.0032.72110272.680.95785.55-39.187119.284.1316.0016.73
6.LAURUSLABS1970.3597.37106460.420.10362.07123.942026.3129.1018.2031.50
7.DRREDDY1161.0030.0796906.380.69435.60-69.108099.80-5.2113.7510.63
8.AUROPHARMA1675.4525.9796401.690.241032.0325.229150.3517.4412.7620.54
9.LUPIN2096.0017.3495842.920.861416.9816.018276.8934.2828.8629.59
10.MANKIND2277.0046.0494050.370.04574.0929.124030.5912.8913.2426.30
11.GLENMARK2416.9037.9468210.880.10482.83927.884018.4831.3520.3520.03
12.NATCOPHARM815.1012.7614599.250.61206.50-57.01735.20-44.6817.1636.83
Detailed Comparison with:

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
1,0489306259651,2371,2934081,1571,1931,264529609597
545488387512474502378596653712408516543
Operating Profit504442238453763791295615405521209254
OPM %48.05%47.53%38.11%46.92%61.69%61.17%7.21%48.49%45.25%43.70%22.75%15.18%9.00%
152530364051168626093557348
Interest3344433931281010
Depreciation40404052404244945448424643
Profit before Tax475424224432758797150521543586125110102
Tax %14.71%15.05%14.13%19.28%16.06%17.04%16.90%17.80%14.51%14.52%14.62%-90.55%26.86%
Net Profit40536019234963666112542846450110721075
22.4320.1110.7219.4935.5336.916.9723.9025.9127.975.9711.704.17

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
1,9582,0911,9861,7901,6541,7682,3513,5694,0943,5952,998
1,2661,1631,1701,2121,2381,5551,5301,9321,9522,2902,180
Operating Profit6929288165784152138211,6372,1421,305819
OPM %35.34%44.39%41.11%32.29%25.11%12.05%34.91%45.87%52.32%36.30%27.31%
133913012410495109105324281270
Interest181519211113914203239
Depreciation54668098115138151172220190178
Profit before Tax6348888475833921567711,5552,2261,364923
Tax %21.97%21.34%21.28%18.62%21.09%10.78%17.33%15.99%16.87%6.06%3.38%
Net Profit4956986674743101396371,3071,8501,282892
EPS28.2439.2436.1026.0116.967.6334.9072.99103.3771.59—
Dividend Payout %23.81%21.80%17.10%25.89%30.96%59.04%15.75%13.01%5.80%6.98%—

COMPOUNDED SALES GROWTH

10 Years:
13%
5 Years:
17%
3 Years:
15%

COMPOUNDED PROFIT GROWTH

10 Years:
22%
5 Years:
33%
3 Years:
26%

STOCK PRICE CAGR

10 Years:
2%
5 Years:
-4%
3 Years:
0%
1 Year:
-4%

RETURN ON EQUITY

10 Years:
19%
5 Years:
18%
3 Years:
23%
Last Year:
16%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Corporate actions

2026

Aug 20

₹ 0.75

Rs.1.5000 per share(75%)Interim Dividend

2026

Feb 18

₹ 0.75

Rs.1.5000 per share(75%)Interim Dividend

2025

Nov 20

₹ 0.75

Rs.1.5000 per share(75%)Interim Dividend

2025

Aug 19

₹ 1

Rs.2.0000 per share(100%)Interim Dividend

2025

Feb 18

₹ 0.75

Rs.1.5000 per share(75%)Interim Dividend

2024

Nov 27

₹ 0.75

Rs.1.5000 per share(75%)Interim Dividend

2024

Aug 23

₹ 1.50

Rs.3.0000 per share(150%)Interim Dividend

2024

Feb 26

₹ 0.62

Rs.1.2500 per share(62.5%)Interim Dividend

2023

Nov 24

₹ 0.62

Rs.1.2500 per share(62.5%)Interim Dividend

2023

Aug 22

₹ 3.50

Rs.7.0000 per share(350%)Interim Dividend

2023

Feb 21

₹ 0.62

Rs.1.2500 per share (62.5%) Third Interim Dividend

2022

Nov 21

₹ 0.37

Re.0.75000 per share (37.50%) Second Interim Dividend

2022

Aug 19

₹ 1.75

Rs.3.5000 per share(175%)Interim Dividend

2022

Feb 24

₹ 1

Rs.2.0000 per share (100%) Third Interim Dividend

2021

Nov 23

₹ 0.25

Re.0.5000 per share (25%) Second Interim Dividend

2021

Aug 24

₹ 1

Rs.2.0000 per share(100%)Interim Dividend

2021

Feb 22

₹ 0.50

Rs.1.0000 per share (50%) Third Interim Dividend

2020

Nov 24

₹ 1.50

Rs.3.0000 per share (150%) Second Interim Dividend

2020

Jun 26

₹ 0.50

Re. 1.0000 per share (50%) Fourth Interim Dividend

2020

Feb 24

₹ 1.75

Rs.3.50/- (175%) Third Interim Dividend

2018

Aug 20

₹ 0.75

Rs.1.5000 per share(75%)Interim Dividend

2018

Feb 15

₹ 3.50

Rs.7.0000 per share (350%) Second Interim Dividend

2017

Aug 16

Rs.1.2500 per share(62.5%)Interim Dividend

2017

Feb 23

₹ 3

Rs.6.0000 per share(300%)Third Interim Dividend

2016

Aug 19

Rs.0.7500 per share(37.5%)Interim Dividend

2016

Feb 22

Rs.1.2500 per share(62.5%)Interim Dividend

2026

Sep 7

₹ 0.75

Rs.1.5000 per share(75%)Interim Dividend

Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital35373636363636363636
1,6493,0643,4963,8104,0374,1524,6665,5567,2988,517
221174385328273415172383279413
Trade Payables251245202234140141182183225365
190216237239266234332388391732
Total Liabilities2,3473,7364,3564,6474,7524,9785,3886,5478,22910,063
8291,0151,2151,5742,0062,1742,2342,2872,5172,615
Capital Work in Progress33648063851822312963134225293
951502441913375506587428553,265
337426508524769698616597642724
000651581,0771,178760
Cash & Bank25172263542631014128651,8571,187
7251,4931,4881,7791,1491,3121,3978469541,219
Total Assets2,3473,7364,3564,6474,7524,9785,3886,5478,22910,063

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
452681874528260909331,1961,6621,776
Cash from Investing-291-1,131-645-165-3-92-437-960-1,444-2,078
Cash from Financing-46652-52-261-18336-347-237-212302
-6-31-4-311-160

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026

Shareholding Pattern

Numbers in percentages

Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
49.7149.6249.6249.5649.5649.4849.4849.4249.42
17.4517.5117.9417.4915.5214.0915.1617.3716.99
7.866.755.585.475.645.875.385.455.62
Government0.000.000.000.000.000.000.000.000.00
24.9726.1226.8827.4629.2830.5629.9727.7627.98

Documents

Corporate disclosures, annual reports, credit ratings, and concall transcripts

2026-09-09
Rights Issue

2026-09-09 - Intimation of Draft letter of Offer

2026-09-09
Outcome of Board Meeting

2026-09-09 - Natco Pharma Limited has informed the Exchange regarding Outcome of Board Meeting held on September 09, 2026.

2026-09-05
Copy of Newspaper Publication

2026-09-05 - Natco Pharma Limited has informed the Exchange about Copy of Newspaper Publication

2026-09-04
Shareholders meeting

2026-09-04 - Natco Pharma Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on September 30, 2026

2026-09-02
Analysts/Institutional Investor Meet/Con. Call Updates

2026-09-02 - Natco Pharma Limited has informed the Exchange about Schedule of meet

2026-08-25
Press Release

2026-08-25 - Natco Pharma Limited has informed the Exchange regarding a press release dated August 25, 2026, titled "Investment in eGenesis, Inc.".

2026-08-24
Analysts/Institutional Investor Meet/Con. Call Updates

2026-08-24 - Natco Pharma Limited has informed the Exchange about Schedule of meet

2026-08-21
Press Release

2026-08-21 - Natco Pharma Limited has informed the Exchange regarding a press release dated August 21, 2026, titled "Conclusion of US FDA Inspection at our Visakhapatnam, Andhra Pradesh, Finished Dosage Formulations (FDF) Unit".

2026-08-19
Analysts/Institutional Investor Meet/Con. Call Updates

2026-08-19 - Natco Pharma Limited has informed the Exchange about Schedule of meet

News

Recent coverage and analyst commentary for NATCOPHARM

Loading news…

🤖

AI Stock Analyst

Natco Pharma Ltd.

🔒

Sign in to Chat with AI

Log in with your 5nance account to ask institutional questions about performance, financials, and outlook.

✨ Sign In to Chat

Free 5nance Account

5nance5nance

Stock analysis and screening tool

5nanceAI © 2020-2026

Made with ❤️ in India.

Data provided by Accord Fintech

Terms & Privacy.

Product

PremiumWhat's new?Learn

Team

About usSupport

Theme

5nance5nance

Product

PremiumWhat's new?Learn

Team

About usSupport

Theme

5nanceAI © 2020-2026

Data provided by Accord Fintech

Made with ❤️ in India.

HomeScreens
Login